European Journal of Clinical Pharmacology

, Volume 69, Issue 3, pp 347–356 | Cite as

Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials




Attention deficit hyperactivity disorder (ADHD) in adulthood is increasingly diagnosed and treated. Methylphenidate is frequently advocated as a first-line pharmacological treatment.


The aim of our study was to compare all-cause discontinuation rate of methylphenidate and its pharmaceutical presentations with placebo in adults with ADHD.


This was a systematic review and meta-analysis of randomized controlled trials comparing methylphenidate with placebo in adults with ADHD. All-cause treatment discontinuation was the primary endpoint. The efficacy in reducing ADHD symptoms and safety were the secondary endpoints.


Twelve studies (2,496 patients) met the inclusion criteria. Four racemic methylphenidate and one dexmethylphenidate presentations were investigated. The rate of all-cause treatment discontinuation was greater with methylphenidate than with placebo, but this difference was not statistically significant [odds ratio (OR) 1.19, 95 % confidence interval (95 % CI) 0.82–1.74, P = 0.37, I2 = 64 %] This finding reached the conventional threshold of statistical significance after one outlier study was excluded (OR 1.44, 95 % CI 1.14–1.82, P = 0.002, I2 = 0). Methylphenidate was more efficacious than placebo for reducing ADHD symptoms and it was associated with a higher proportion of patients dropping out due to adverse effects.


Despite reducing ADHD symptoms, methylphenidate showed no advantage over placebo in terms of treatment discontinuation. More attention should be given in the future to the endpoint “all-cause treatment discontinuation” when making regulatory decisions and developing clinical guidelines involving the treatment of ADHD in adulthood.


Attention deficit hyperactivity disorder Adulthood Methylphenidate All-cause treatment discontinuation Meta-analysis 

Supplementary material

228_2012_1390_MOESM1_ESM.doc (60 kb)
ESM 1(DOC 60 kb)
228_2012_1390_MOESM2_ESM.doc (80 kb)
ESM 2(DOC 79 kb)
228_2012_1390_MOESM3_ESM.doc (58 kb)
ESM 3(DOC 58 kb)
228_2012_1390_MOESM4_ESM.doc (63 kb)
ESM 4(DOC 63 kb)
228_2012_1390_MOESM5_ESM.doc (61 kb)
ESM 5(DOC 61 kb)
228_2012_1390_MOESM6_ESM.doc (64 kb)
ESM 6(DOC 64 kb)
228_2012_1390_MOESM7_ESM.doc (80 kb)
ESM 7(DOC 80 kb)
228_2012_1390_MOESM8_ESM.doc (60 kb)
ESM 8(DOC 60 kb)


  1. 1.
    Fayyad J, De Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, Girolamo D (2007) Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 190:402–409PubMedCrossRefGoogle Scholar
  2. 2.
    Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617–627PubMedCrossRefGoogle Scholar
  3. 3.
    Simon V, Czobor P, Bálint S, Mészáros A, Bitter I (2009) Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 194:204–211PubMedCrossRefGoogle Scholar
  4. 4.
    Biederman J (2004) Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 65[Suppl 3]:3–7PubMedGoogle Scholar
  5. 5.
    Langley K, Fowler T, Ford T, Thapar AK, van den Bree M, Harold G, Owen MJ, O’Donovan MC, Thapar A (2010) Adolescent clinical outcomes for young people with attention-deficit hyperactivity disorder. Br J Psychiatry 196:235–240PubMedCrossRefGoogle Scholar
  6. 6.
    Levin FR, Evans SM, McDowell DM, Kleber (1998) Methylphenidate treatment for cocaine abusers with attention-deficit hyperactivity disorder: a pilot study. J Clin Psychiatry 59:300–305PubMedCrossRefGoogle Scholar
  7. 7.
    Barkley RA, Murphy KR, Dupaul GI, Bush T (2002) Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc 8:655–672PubMedCrossRefGoogle Scholar
  8. 8.
    Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M (2006) Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 67:524–540PubMedCrossRefGoogle Scholar
  9. 9.
    Castells X, Ramos-Quiroga JA, Rigau D, Bosch R, Nogueira M, Vidal X, Casas M (2011) Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 25:157–169PubMedCrossRefGoogle Scholar
  10. 10.
    Faraone SV, Glatt SJ (2010) A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 71:754–763PubMedCrossRefGoogle Scholar
  11. 11.
    Koesters M, Becker T, Kilian R, Fegert JM, Weinmann S (2009) Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 23:733–744PubMedCrossRefGoogle Scholar
  12. 12.
    Godfrey J (2009) Safety of therapeutic methylphenidate in adults: a systematic review of the evidence. J Psychopharmacol 23:194–205PubMedCrossRefGoogle Scholar
  13. 13.
    Merkel RL Jr, Kuchibhatla A (2009) Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I. Expert Opin Drug Saf 8:655–668PubMedCrossRefGoogle Scholar
  14. 14.
    Rösler M, Casas M, Konofal E, Buitelaar J (2010) Attention deficit hyperactivity disorder in adults. World J Biol Psychiatry 11:684–698PubMedCrossRefGoogle Scholar
  15. 15.
    Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA) (2011) Canadian ADHD practice guidelines, 3rd edn. CADDRA, TorontoGoogle Scholar
  16. 16.
    Dodson WW (2005) Pharmacotherapy of adult ADHD. J Clin Psychol 61:589–606PubMedCrossRefGoogle Scholar
  17. 17.
    National Institute for Health and Clinical Excellence (NICE) (2008) Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. Clinical guidelines CG72, September 2008. NICE, LondonGoogle Scholar
  18. 18.
    Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, Morris KA, Santosh P, Sonuga-Barke E, Taylor E, Weiss M, Young S, British Association for Psychopharmacology (2007) Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 21:10–41PubMedCrossRefGoogle Scholar
  19. 19.
    Swanson J (2003) Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement. CNS Drugs 17:117–131PubMedCrossRefGoogle Scholar
  20. 20.
    Hollingworth SA, Nissen LM, Stathis SS, Siskind DJ, Varghese JM, Scott JG (2011) Australian national trends in stimulant dispensing: 2002–2009. Aust N Z J Psychiatry 45:332–336PubMedCrossRefGoogle Scholar
  21. 21.
    Treceño C, Martín Arias LH, Sáinz M, Salado I, García Ortega P, Velasco V, Jimeno N, Escudero A, Velasco A, Carvajal A (2012) Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate. Pharmacoepidemiol Drug Saf. 21(4):435–41Google Scholar
  22. 22.
    Trip AM, Visser ST, Kalverdijk LJ, de Jong-van den Berg LT (2003) Large increase of the use of psycho-stimulants among youth in the Netherlands between 1996 and 2006. Br J Clin Pharmacol 67:466–468CrossRefGoogle Scholar
  23. 23.
    Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, Greenhill L, Cooper T (2009) Sudden death and use of stimulant medications in youths. Am J Psychiatry 166:992–1001PubMedCrossRefGoogle Scholar
  24. 24.
    Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E, European Guidelines Group (2011) European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 20:17–37PubMedCrossRefGoogle Scholar
  25. 25.
    Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A (2007) Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 120:1494–1501CrossRefGoogle Scholar
  26. 26.
    Ramos-Quiroga JA, Casas M (2011) Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder. CNS Drugs 25:17–36PubMedCrossRefGoogle Scholar
  27. 27.
    Weiss MD, Gadow K, Wasdell MB (2006) Effectiveness outcomes in attention-deficit/hyperactivity disorder. J Clin Psychiatry 67[Suppl 8]:38–45PubMedGoogle Scholar
  28. 28.
    Egger M, Dickersin K, Davey Smith D (2007) Problems and limitations in conducting systematic reviews. In: Egger M, Davey Smith D, Altman DG (eds) Systematic reviews in healthcare. Meta-analysis in context. BMJ Publishing Group, London, pp 43–68Google Scholar
  29. 29.
    Anderson IM, Tomenson BM (1995) Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. Br Med J 310:1433–1438CrossRefGoogle Scholar
  30. 30.
    McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, Thase ME, Davis L, Biggs MM, Shores-Wilson K, Luther JF, Niederehe G, Warden D, Rush AJ (2006) Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 163:1531–1541PubMedCrossRefGoogle Scholar
  31. 31.
    Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR (2011) Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 378:1306–1315PubMedCrossRefGoogle Scholar
  32. 32.
    Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE (2000) A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 343:1290–1297PubMedCrossRefGoogle Scholar
  33. 33.
    Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223PubMedCrossRefGoogle Scholar
  34. 34.
    Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Döpfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E (2006) Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15:476–495PubMedCrossRefGoogle Scholar
  35. 35.
    European Medicine Agency (EMA): Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD). Available at: Accessed 2 Nov 2011
  36. 36.
    Peterson K, McDonagh MS, Fu R (2008) Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology (Berlin) 197:1–11CrossRefGoogle Scholar
  37. 37.
    Higgins JPT, Green S (2011) Strategies for addressing heterogeneity. Cochrane Handbook for Systematic Reviews of interventions Version 5.1.0. (updated March 2011). The Cochrane Collaboration Available from
  38. 38.
    Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A (2002) Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 31:140–149PubMedCrossRefGoogle Scholar
  39. 39.
    The Nordic Cochrane Centre (2011) Review Manager (RevMan), ver. 5.1 (computer program). The Nordic Cochrane Centre, The Cochrane Collaboration, CopenhagenGoogle Scholar
  40. 40.
    StataCorp LP (2007) STATA ver. 10 (computer program). STataCorp LP, College Station, TXGoogle Scholar
  41. 41.
    Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T (2009) Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose escalation study. J Clin Psychopharmacol 29:239–247PubMedCrossRefGoogle Scholar
  42. 42.
    Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T (2006) A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 59:829–835, Erratum in: Biol Psychiatry 2007; 61:1402PubMedCrossRefGoogle Scholar
  43. 43.
    Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Kotarski M, Spencer T (2010) A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 30:549–553PubMedCrossRefGoogle Scholar
  44. 44.
    Casas M, Rösler M, Sandra Kooij JJ, Ginsberg Y, Ramos-Quiroga JA, Heger S, Berwaerts J, Dejonckheere J, van der Vorst E, Schäuble B (2011) Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: A 13-week, randomized, double-blind, placebo-controlled, fixed-dose study. World J Biol Psychiatry. doi:10.3109/15622975.2011.600333
  45. 45.
    Levin ED, Conners CK, Silva D, Canu W, March J (2001) Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol 9:83–90PubMedCrossRefGoogle Scholar
  46. 46.
    Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE, Lee E, Buitelaar JK (2008) A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatr 63:981–989CrossRefGoogle Scholar
  47. 47.
    Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK (2007) A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 68:93–101PubMedCrossRefGoogle Scholar
  48. 48.
    Retz W, Rösler M, Ose C, Scherag A, Alm B, Philipsen A, Fischer R, Ammer R (2012) Multiscale assessment of treatment efficacy in adults with ADHD: A randomized placebo-controlled, multi-centre study with extended-release methylphenidate. World J Biol Psychiatry 13:48–59PubMedCrossRefGoogle Scholar
  49. 49.
    Rösler M, Fischer R, Ammer R, Ose C, Retz W (2009) A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 259:120–129PubMedCrossRefGoogle Scholar
  50. 50.
    Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K (1995) A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 52:434–443PubMedCrossRefGoogle Scholar
  51. 51.
    Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, Mick E, Aleardi M, Herzig K, Faraone S (2005) A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 57:456–463PubMedCrossRefGoogle Scholar
  52. 52.
    Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L, Adult ADHD Research Group (2007) Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 61:1380–1387PubMedCrossRefGoogle Scholar
  53. 53.
    Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N, Edwards A, Donlin J, Pihlgren E (2002) Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 10:286–294PubMedCrossRefGoogle Scholar
  54. 54.
    Winhusen TM, Somoza EC, Brigham GS, Liu DS, Green CA, Covey LS, Croghan IT, Adler LA, Weiss RD, Leimberger JD, Lewis DF, Dorer EM (2010) Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 71:1680–1688PubMedCrossRefGoogle Scholar
  55. 55.
    Patrick KS, González MA, Straughn AB, Markowitz JS (2005) New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Drug Deliv 2:121–143PubMedCrossRefGoogle Scholar
  56. 56.
    Wilens TE, Biederman J, Lerner M, Concerta Study Group (2004) Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. J Clin Psychopharmacol 24:36–41PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.Department of Medical SciencesTransLab research group, Universitat de GironaGironaSpain
  2. 2.Parc Sanitari Sant Joan de DéuUnitat d’Hospitalització Psiquiàtrica PenitenciàriaBarcelonaSpain

Personalised recommendations